Dengwen Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Dengwen Zhang has a total of 40 co-authors. Here are the top co-authors by number of shared publications:
- Yin Cai
The Hong Kong Polytechnic University
4 shared publications Yuke Tian
Department of Anesthesiology, Tongji Hospital Affiliated to Tongji Medical College, Huazhong University of Science and Technology, Anhui Sheng, China
3 shared publications- Zhengyuan Xia
Department of Anesthesiology and Perioperative Medicine, Zhengzhou Central Hospital Affiliated to Zhengzhou University
3 shared publications Chuanhan Zhang
Department of Anesthesiology, Tongji Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan 430030, China
2 shared publicationsHaifeng Li
Guangdong General Hospital
2 shared publicationsHao Liu
Department of Anesthesiology, Guangzhou Medical University Second Affiliated Hospital, Guangzhou, China
2 shared publications
Latest Publications
- Open Access
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 108
ANGPTL4 attenuates hypoxia/reoxygenation-induced cardiomyocyte apoptosis via activation of Akt signaling
ID 15237 Poster Board 108 Ischemic heart disease (IHD) is a leading cause for morbidity and mortality worldwide. Reperfusion therapy restores blood flow, but paradoxically exacerbates myocardial injury, known as ischemia/reperfusion injury (I/RI). Apoptotic cell death is one of the main forms of post-ischemic cell death. Thus, inhibiting apoptosis may limit the extent of I/RI and lead to better prognosis of post-ischemic myocardial recovery. ANGPTL4, a gene known to regulate lipid metabolism, has been shown to preserve vascular integrity, reduce no-reflow and thus attenuate myocardial I/RI in rabbits. However, whether ANGPTL4 directly impacts cardiomyocytes and alleviates myocardial I/RI through reducing cell apoptosis is unknown . Therefore, we explored whether ANGPTL4 protects against hypoxia/reoxygenation (H/R)-induced cardiomyocyte injury through inhibiting apoptosis. In vivo myocardial I/R model was induced by occluding the left anterior descending (LAD) artery for 30 mins, followed by 2 h reperfusion. Sham operations were performed by passing a silk thread under the LAD without occlusion. Infarct size was determined by using Evans blue/TTC staining. The rat cardiomyocyte-derived cell line H9C2 was transfected with scramble or ANGPTL4 siRNA, followed by H/R (6 hours hypoxia followed by 12 h reoxygenation) in the absence or presence of pre-treatment with SC-79 (4 μg/mL, 1h, selective Akt activator) or LW-6 (20 μM, 2h, selective HIF-1α inhibitor). Cell damage was assessed by measuring Lactate dehydrogenase (LDH) release and cell viability by MTT assay. Protein levels of apoptosis markers [Bcl-2, Bax, cleaved caspase 3] and proteins related to pro-survival signaling pathway [Akt and phosphorylated Akt (S473)] were determined by Western blotting. The result showed that ANGPTL4 increased significantly in the mouse myocardium after I/RI and in H/R-stimulated H9C2 cardiomyocytes, indicating that ANGPTL4 in cardiomyocytes may be involved in the pathogenesis of myocardial I/RI. Indeed, knockdown of ANGPTL4 in H9C2 cells with ANGPTL4 siRNA significantly aggravated H/R-induced cell injury (increased LDH level and reduced cell viability) and exacerbated cell apoptosis (greater cleaved caspase 3 expression and Bax/Bcl-2 ratio). Activation of Akt is well known to protect against myocardial I/RI via inhibition of cell apoptosis. In the present study, a significant reduction in p-Akt (S473) was observed in the ANGPTL4-knockdown cells upon H/R stimulation, suggesting that inhibition of ANGPTL4 may exacerbate H/R-induced cell apoptosis via down-regulation of Akt signaling pathway. Indeed, pre-treatment with SC-79 significantly reversed H/R-induced cell apoptosis in ANGPTL4 knockdown H9C2 cardiomyocytes, as evidenced by decreased cleaved caspase 3 expression and Bax/Bcl-2 ratio. Furthermore, HIF-1α is known to be the major transcription factor activated in hypoxia in ischemic conditions. The induction of ANGPTL4 was significantly reduced when H/R-stimulated H9C2 cardiomyocytes were pre-treated with LW-6, indicating that HIF-1α may upregulate ANGPTL4 upon H/R stimulation. It is concluded that upon H/R stimulation, HIF-1α-mediated upregulation of ANGPTL4 may protect against H/R-induced cardiomyocyte injury through activating Akt signaling. This study was supported by Joint Postdoc Scheme (P0038982), Guangdong Basic and Applied Basic Research Foundation (2022A1515011116, 2019A1515110063) and National Natural Science Foundation of China (82002095).
- 18 May 2023
- Published by Elsevier in The Journal of Pharmacology and Experimental Therapeutics
- Vol. 385 (S3) , 108
Open AccessANGPTL4 attenuates hypoxia/reoxygenation-induced cardiomyocyte apoptosis via activation of Akt signaling
ID 15237 Poster Board 108 Ischemic heart disease (IHD) is a leading cause for morbidity and mortality worldwide. Reperfusion therapy restores blood flow, but paradoxically exacerbates myocardial injury, known as ischemia/reperfusion injury (I/RI). Apoptotic cell death is one of the main forms of post-ischemic cell death. Thus, inhibiting apoptosis may limit the extent of I/RI and lead to better prognosis of post-ischemic myocardial recovery. ANGPTL4, a gene known to regulate lipid metabolism, has been shown to preserve vascular integrity, reduce no-reflow and thus attenuate myocardial I/RI in rabbits. However, whether ANGPTL4 directly impacts cardiomyocytes and alleviates myocardial I/RI through reducing cell apoptosis is unknown . Therefore, we explored whether ANGPTL4 protects against hypoxia/reoxygenation (H/R)-induced cardiomyocyte injury through inhibiting apoptosis. In vivo myocardial I/R model was induced by occluding the left anterior descending (LAD) artery for 30 mins, followed by 2 h reperfusion. Sham operations were performed by passing a silk thread under the LAD without occlusion. Infarct size was determined by using Evans blue/TTC staining. The rat cardiomyocyte-derived cell line H9C2 was transfected with scramble or ANGPTL4 siRNA, followed by H/R (6 hours hypoxia followed by 12 h reoxygenation) in the absence or presence of pre-treatment with SC-79 (4 μg/mL, 1h, selective Akt activator) or LW-6 (20 μM, 2h, selective HIF-1α inhibitor). Cell damage was assessed by measuring Lactate dehydrogenase (LDH) release and cell viability by MTT assay. Protein levels of apoptosis markers [Bcl-2, Bax, cleaved caspase 3] and proteins related to pro-survival signaling pathway [Akt and phosphorylated Akt (S473)] were determined by Western blotting. The result showed that ANGPTL4 increased significantly in the mouse myocardium after I/RI and in H/R-stimulated H9C2 cardiomyocytes, indicating that ANGPTL4 in cardiomyocytes may be involved in the pathogenesis of myocardial I/RI. Indeed, knockdown of ANGPTL4 in H9C2 cells with ANGPTL4 siRNA significantly aggravated H/R-induced cell injury (increased LDH level and reduced cell viability) and exacerbated cell apoptosis (greater cleaved caspase 3 expression and Bax/Bcl-2 ratio). Activation of Akt is well known to protect against myocardial I/RI via inhibition of cell apoptosis. In the present study, a significant reduction in p-Akt (S473) was observed in the ANGPTL4-knockdown cells upon H/R stimulation, suggesting that inhibition of ANGPTL4 may exacerbate H/R-induced cell apoptosis via down-regulation of Akt signaling pathway. Indeed, pre-treatment with SC-79 significantly reversed H/R-induced cell apoptosis in ANGPTL4 knockdown H9C2 cardiomyocytes, as evidenced by decreased cleaved caspase 3 expression and Bax/Bcl-2 ratio. Furthermore, HIF-1α is known to be the major transcription factor activated in hypoxia in ischemic conditions. The induction of ANGPTL4 was significantly reduced when H/R-stimulated H9C2 cardiomyocytes were pre-treated with LW-6, indicating that HIF-1α may upregulate ANGPTL4 upon H/R stimulation. It is concluded that upon H/R stimulation, HIF-1α-mediated upregulation of ANGPTL4 may protect against H/R-induced cardiomyocyte injury through activating Akt signaling. This study was supported by Joint Postdoc Scheme (P0038982), Guangdong Basic and Applied Basic Research Foundation (2022A1515011116, 2019A1515110063) and National Natural Science Foundation of China (82002095).
- Open Access
- 16 February 2020
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 11 (5) , 1126-1136
Activation of autophagy inhibits nucleotide‐binding oligomerization domain‐like receptor protein 3 inflammasome activation and attenuates myocardial ischemia‐reperfusion injury in diabetic rats
Aims/Introduction: Diabetic hearts are more vulnerable to ischemia‐reperfusion injury (I/RI). The activation of nucleotide‐binding oligomerization domain‐like receptor protein 3 (NLRP3) inflammasome can mediate the inflammatory process, and hence might contribute to myocardial I/RI. Activation of autophagy can eliminate excess reactive oxygen species and alleviate myocardial I/RI in diabetes. The present study aimed to investigate whether the activation of autophagy can alleviate diabetic myocardial I/RI through inhibition of NLRP3 inflammasome activation.Materials and Methods: A dose of 65 mg/kg streptozotocin was given by tail vein injection to establish a type 1 diabetes model in the rats. The left anterior descending coronary artery was ligated for 30 min followed by reperfusion for 2 h to establish a myocardial I/RI model. H9C2 cardiomyocytes were exposed to high glucose (33 mmol/L) and subjected to hypoxia–reoxygenation (6 h hypoxia followed by 4 h reoxygenation).Results: The diabetic rats showed significant inhibition of cardiac autophagy (decreased LC3‐II/I and increased p62) that was concomitant with increased activation of NLRP3 inflammasome (increased NLRP3, apoptosis‐related spots protein cleaved caspase‐1, interleukin‐18, interleukin‐1β) and more severe myocardial I/RI (elevated creatine kinase myocardial band, lactate dehydrogenase and larger infarct size). However, administration of rapamycin, an inhibitor of the autophagy, to activate autophagy resulted in the inhibition of NLRP3 inflammasome, and finally alleviated myocardial I/RI. In vitro, high glucose inhibited autophagy, while activating NLRP3 inflammasome in H9C2 cardiomyocytes and aggravating hypoxia–reoxygenation injury, but rapamycin reversed these adverse effects of high glucose.Conclusion: Activation of autophagy can suppress the formation of NLRP3 inflammasome, which in turn attenuates myocardial ischemia‐reperfusion injury in diabetic rats.
- 16 February 2020
- Published by Wiley in Journal of Diabetes Investigation
- Vol. 11 (5) , 1126-1136
Open AccessActivation of autophagy inhibits nucleotide‐binding oligomerization domain‐like receptor protein 3 inflammasome activation and attenuates myocardial ischemia‐reperfusion injury in diabetic rats
Aims/Introduction: Diabetic hearts are more vulnerable to ischemia‐reperfusion injury (I/RI). The activation of nucleotide‐binding oligomerization domain‐like receptor protein 3 (NLRP3) inflammasome can mediate the inflammatory process, and hence might contribute to myocardial I/RI. Activation of autophagy can eliminate excess reactive oxygen species and alleviate myocardial I/RI in diabetes. The present study aimed to investigate whether the activation of autophagy can alleviate diabetic myocardial I/RI through inhibition of NLRP3 inflammasome activation.Materials and Methods: A dose of 65 mg/kg streptozotocin was given by tail vein injection to establish a type 1 diabetes model in the rats. The left anterior descending coronary artery was ligated for 30 min followed by reperfusion for 2 h to establish a myocardial I/RI model. H9C2 cardiomyocytes were exposed to high glucose (33 mmol/L) and subjected to hypoxia–reoxygenation (6 h hypoxia followed by 4 h reoxygenation).Results: The diabetic rats showed significant inhibition of cardiac autophagy (decreased LC3‐II/I and increased p62) that was concomitant with increased activation of NLRP3 inflammasome (increased NLRP3, apoptosis‐related spots protein cleaved caspase‐1, interleukin‐18, interleukin‐1β) and more severe myocardial I/RI (elevated creatine kinase myocardial band, lactate dehydrogenase and larger infarct size). However, administration of rapamycin, an inhibitor of the autophagy, to activate autophagy resulted in the inhibition of NLRP3 inflammasome, and finally alleviated myocardial I/RI. In vitro, high glucose inhibited autophagy, while activating NLRP3 inflammasome in H9C2 cardiomyocytes and aggravating hypoxia–reoxygenation injury, but rapamycin reversed these adverse effects of high glucose.Conclusion: Activation of autophagy can suppress the formation of NLRP3 inflammasome, which in turn attenuates myocardial ischemia‐reperfusion injury in diabetic rats.
- Open Access
- 17 April 2019
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2019, 1-15
miR-181c-5p Exacerbates Hypoxia/Reoxygenation-Induced Cardiomyocyte Apoptosis via Targeting PTPN4
Background. Activation of cell apoptosis is a major form of cell death during myocardial ischemia/reperfusion injury (I/RI). Therefore, examining ways to control cell apoptosis has important clinical significance for improving postischemic recovery. Clinical evidence demonstrated that miR-181c-5p was significantly upregulated in the early phase of myocardial infarction. However, whether or not miR-181c-5p mediates cardiac I/RI through cell apoptosis pathway is unknown. Thus, the present study is aimed at investigating the role and the possible mechanism of miR-181c-5p in apoptosis during I/R injury by using H9C2 cardiomyocytes. Methods and Results. The rat origin H9C2 cardiomyocytes were subjected to hypoxia/reoxygenation (H/R, 6 hours hypoxia followed by 6 hours reoxygenation) to induce cell injury. The results showed that H/R significantly increased the expression of miR-181c-5p but not miR-181c-3p in H9C2 cells. In line with this, in an in vivo rat cardiac I/RI model, miR-181c-5p expression was also significantly increased. The overexpression of miR-181c-5p by its agomir transfection significantly aggravated H/R-induced cell injury (increased lactate dehydrogenase level and reduced cell viability) and exacerbated H/R-induced cell apoptosis (greater cleaved caspases 3 expression, Bax/Bcl-2 and more TUNEL-positive cells). In contrast, inhibition of miR-181c-5p in vitro had the opposite effect. By using computational prediction algorithms, protein tyrosine phosphatase nonreceptor type 4 (PTPN4) was predicted as a potential target gene of miR-181c-5p and was verified by the luciferase reporter assay. The overexpression of miR-181c-5p significantly attenuated the mRNA and protein expression of PTPN4 in H9C2 cardiomyocytes. Moreover, knockdown of PTPN4 significantly aggravated H/R-induced enhancement of LDH level, cleaved caspase 3 expression, and apoptotic cell death, which mimicked the proapoptotic effects of miR-181c-5p in H9C2 cardiomyocytes. Conclusions. These findings suggested that miR-181c-5p exacerbates H/R-induced cardiomyocyte injury and apoptosis via targeting PTPN4 and that miR-181c-5p/PTPN4 signaling may yield novel strategies to combat myocardial I/R injury.
- 17 April 2019
- Published by Wiley in Oxidative Medicine and Cellular Longevity
- Vol. 2019, 1-15
Open AccessmiR-181c-5p Exacerbates Hypoxia/Reoxygenation-Induced Cardiomyocyte Apoptosis via Targeting PTPN4
Background. Activation of cell apoptosis is a major form of cell death during myocardial ischemia/reperfusion injury (I/RI). Therefore, examining ways to control cell apoptosis has important clinical significance for improving postischemic recovery. Clinical evidence demonstrated that miR-181c-5p was significantly upregulated in the early phase of myocardial infarction. However, whether or not miR-181c-5p mediates cardiac I/RI through cell apoptosis pathway is unknown. Thus, the present study is aimed at investigating the role and the possible mechanism of miR-181c-5p in apoptosis during I/R injury by using H9C2 cardiomyocytes. Methods and Results. The rat origin H9C2 cardiomyocytes were subjected to hypoxia/reoxygenation (H/R, 6 hours hypoxia followed by 6 hours reoxygenation) to induce cell injury. The results showed that H/R significantly increased the expression of miR-181c-5p but not miR-181c-3p in H9C2 cells. In line with this, in an in vivo rat cardiac I/RI model, miR-181c-5p expression was also significantly increased. The overexpression of miR-181c-5p by its agomir transfection significantly aggravated H/R-induced cell injury (increased lactate dehydrogenase level and reduced cell viability) and exacerbated H/R-induced cell apoptosis (greater cleaved caspases 3 expression, Bax/Bcl-2 and more TUNEL-positive cells). In contrast, inhibition of miR-181c-5p in vitro had the opposite effect. By using computational prediction algorithms, protein tyrosine phosphatase nonreceptor type 4 (PTPN4) was predicted as a potential target gene of miR-181c-5p and was verified by the luciferase reporter assay. The overexpression of miR-181c-5p significantly attenuated the mRNA and protein expression of PTPN4 in H9C2 cardiomyocytes. Moreover, knockdown of PTPN4 significantly aggravated H/R-induced enhancement of LDH level, cleaved caspase 3 expression, and apoptotic cell death, which mimicked the proapoptotic effects of miR-181c-5p in H9C2 cardiomyocytes. Conclusions. These findings suggested that miR-181c-5p exacerbates H/R-induced cardiomyocyte injury and apoptosis via targeting PTPN4 and that miR-181c-5p/PTPN4 signaling may yield novel strategies to combat myocardial I/R injury.
- Open Access
- 1 April 2019
- Published by Wiley in The FASEB Journal
- Vol. 33 (S1) , lb398
Activation of autophagy protects against myocardial ischemic reperfusion injury by inhibition of NLRP3 inflammasome‐mediated pyroptosis and inflammatory responses in diabetic rats
Background: Diabetic hearts are more vulnerable to ischemia/reperfusion injury (I/RI). The activation of NLRP3 inflammasome can mediate pyroptosis and inflammatory responses, which in turn exacerbate myocardial I/RI. Studies have demonstrated that activation of autophagy can eliminate excess reactive oxygen species (ROS) generation and alleviate myocardial I/RI in diabetes. However, the possible regulatory relationship between autophagy and NLRP3 inflammasome during diabetic myocardial I/RI is still unknown. Thus, the present study aimed to investigate whether the activation of autophagy can alleviate diabetic myocardial I/RI via inhibition of NLRP3 inflammasome‐mediated pyroptosis and inflammatory responses. Methods: A dose of 60 mg/kg streptozotocin was given via tail vein injection to establish type 1 diabetes model in rats. The left anterior descending branch of the coronary artery was ligated for 30 minutes and then allowed for reperfusion for 2 hours to establish rat myocardial I/RI model. RapaLink‐1(1mg/kg, i.p.), the third‐generation mTOR inhibitor, was given 72 hours before inducing myocardial I/RI. The degree of I/RI was assessed by the measurement of plasma CK‐MB, cTnT, LDH, and myocardial infarction size. The expression of NLRP3, ACS, cleaved Caspase‐1, interleulin (IL)‐18, and IL‐1β in the myocardium, and the levels of IL‐18 and IL‐1β in the plasma were tested to assess the activation of inflammasome and inflammatory responses. In addition, LC3 □/□ and p62 were measured to evaluate the level of autophagy. Results: Compared to non‐diabetic group, levels of cardiac autophagy were inhibited (decreased LC3 □/□ and increased p62) concomitant with activation of NLRP3 inflammasome (increased NLRP3, ASC, cleaved caspase‐1, IL‐18, IL‐1β) in diabetes. Also, more severe myocardial I/RI (elevated CK‐MB, cTnT, LDH, and larger infarction size) was seen in diabetic rats. Administration of RapaLink‐1 activated autophagy, inhibited NLRP3 inflammasome, and alleviated myocardial I/RI in diabetic rats. Conclusion: The activation of NLRP3 inflammasome in the diabetic myocardium may be attributable to the inhibition of autophagy. The activation of autophagy may inhibit NLRP3 inflammasome activation and consequently alleviate myocardial I/RI in diabetes. Support or Funding Information The study was supported by Guangdong Natural Science Foundation (2018A030313535, Guangdong, China) and HMRF (05161826) of Hong Kong. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
- 1 April 2019
- Published by Wiley in The FASEB Journal
- Vol. 33 (S1) , lb398
Open AccessActivation of autophagy protects against myocardial ischemic reperfusion injury by inhibition of NLRP3 inflammasome‐mediated pyroptosis and inflammatory responses in diabetic rats
Background: Diabetic hearts are more vulnerable to ischemia/reperfusion injury (I/RI). The activation of NLRP3 inflammasome can mediate pyroptosis and inflammatory responses, which in turn exacerbate myocardial I/RI. Studies have demonstrated that activation of autophagy can eliminate excess reactive oxygen species (ROS) generation and alleviate myocardial I/RI in diabetes. However, the possible regulatory relationship between autophagy and NLRP3 inflammasome during diabetic myocardial I/RI is still unknown. Thus, the present study aimed to investigate whether the activation of autophagy can alleviate diabetic myocardial I/RI via inhibition of NLRP3 inflammasome‐mediated pyroptosis and inflammatory responses. Methods: A dose of 60 mg/kg streptozotocin was given via tail vein injection to establish type 1 diabetes model in rats. The left anterior descending branch of the coronary artery was ligated for 30 minutes and then allowed for reperfusion for 2 hours to establish rat myocardial I/RI model. RapaLink‐1(1mg/kg, i.p.), the third‐generation mTOR inhibitor, was given 72 hours before inducing myocardial I/RI. The degree of I/RI was assessed by the measurement of plasma CK‐MB, cTnT, LDH, and myocardial infarction size. The expression of NLRP3, ACS, cleaved Caspase‐1, interleulin (IL)‐18, and IL‐1β in the myocardium, and the levels of IL‐18 and IL‐1β in the plasma were tested to assess the activation of inflammasome and inflammatory responses. In addition, LC3 □/□ and p62 were measured to evaluate the level of autophagy. Results: Compared to non‐diabetic group, levels of cardiac autophagy were inhibited (decreased LC3 □/□ and increased p62) concomitant with activation of NLRP3 inflammasome (increased NLRP3, ASC, cleaved caspase‐1, IL‐18, IL‐1β) in diabetes. Also, more severe myocardial I/RI (elevated CK‐MB, cTnT, LDH, and larger infarction size) was seen in diabetic rats. Administration of RapaLink‐1 activated autophagy, inhibited NLRP3 inflammasome, and alleviated myocardial I/RI in diabetic rats. Conclusion: The activation of NLRP3 inflammasome in the diabetic myocardium may be attributable to the inhibition of autophagy. The activation of autophagy may inhibit NLRP3 inflammasome activation and consequently alleviate myocardial I/RI in diabetes. Support or Funding Information The study was supported by Guangdong Natural Science Foundation (2018A030313535, Guangdong, China) and HMRF (05161826) of Hong Kong. This abstract is from the Experimental Biology 2019 Meeting. There is no full text article associated with this abstract published in The FASEB Journal .
- Open Access
- 1 January 2017
- Published by SAGE Publications in Molecular Pain
- Vol. 13
Intrathecal administration of human bone marrow mesenchymal stem cells genetically modified with human proenkephalin gene decrease nociceptive pain in neuropathic rats
Background: Mesenchymal stem cell (MSC) has been one of the potential tools in neuropathic pain therapy; however, the augmented efficacy may be expected when they are modified with human proenkephalin ( hPPE) gene. In the current study, the antinociceptive effect of human bone marrow stem cells (hBMSCs) engineered with hPPE gene (hPPE-hBMSCs) on sciatic nerve chronic constriction injury (CCI)-induced neuropathic pain in rats was investigated. Methods: Primary-cultured hBMSCs were passaged and modified with hPPE, and the cell suspensions (6 × 106) were then intrathecally injected into a rat model of CCI. Paw mechanical withdrawal threshold and paw withdrawal thermal latency were measured before and after CCI surgery. The effects of hPPE gene transfer on hBMSCs bioactivity were analyzed in vitro and in vivo. Results: No changes were observed in the surface phenotypes and differentiation of hBMSCs after gene transfer. The hPPE-hBMSC group showed improved paw mechanical withdrawal threshold and paw thermal withdrawal latency values on the ipsilateral side of rats with CCI from day 9 post-surgery, and the analgesic effect was reversed by naloxone. Leucine-enkephalin (L-EK) secretion was augmented in the hPPE-engineered hBMSC group. Conclusions: The intrathecal administration of BMSCs modified with hPPE gene can effectively relieve pain caused by chronic constriction injury in rats and might be a potentially therapeutic tool for neuropathic pain in humans.
- 1 January 2017
- Published by SAGE Publications in Molecular Pain
- Vol. 13
Open AccessIntrathecal administration of human bone marrow mesenchymal stem cells genetically modified with human proenkephalin gene decrease nociceptive pain in neuropathic rats
Background: Mesenchymal stem cell (MSC) has been one of the potential tools in neuropathic pain therapy; however, the augmented efficacy may be expected when they are modified with human proenkephalin ( hPPE) gene. In the current study, the antinociceptive effect of human bone marrow stem cells (hBMSCs) engineered with hPPE gene (hPPE-hBMSCs) on sciatic nerve chronic constriction injury (CCI)-induced neuropathic pain in rats was investigated. Methods: Primary-cultured hBMSCs were passaged and modified with hPPE, and the cell suspensions (6 × 106) were then intrathecally injected into a rat model of CCI. Paw mechanical withdrawal threshold and paw withdrawal thermal latency were measured before and after CCI surgery. The effects of hPPE gene transfer on hBMSCs bioactivity were analyzed in vitro and in vivo. Results: No changes were observed in the surface phenotypes and differentiation of hBMSCs after gene transfer. The hPPE-hBMSC group showed improved paw mechanical withdrawal threshold and paw thermal withdrawal latency values on the ipsilateral side of rats with CCI from day 9 post-surgery, and the analgesic effect was reversed by naloxone. Leucine-enkephalin (L-EK) secretion was augmented in the hPPE-engineered hBMSC group. Conclusions: The intrathecal administration of BMSCs modified with hPPE gene can effectively relieve pain caused by chronic constriction injury in rats and might be a potentially therapeutic tool for neuropathic pain in humans.
- Open Access
- 1 January 2017
- Published by Wiley in Pain Research and Management
- Vol. 2017, 1-11
Antinociceptive Effect of Intrathecal Injection of Genetically Engineered Human Bone Marrow Stem Cells Expressing the Human Proenkephalin Gene in a Rat Model of Bone Cancer Pain
Background. This study aimed to investigate the use of human bone marrow mesenchymal stem cells (hBMSCs) genetically engineered with the human proenkephalin (hPPE) gene to treat bone cancer pain (BCP) in a rat model.Methods. Primary cultured hBMSCs were passaged and modified with hPPE, and the cell suspensions (6 × 106) were then intrathecally injected into a rat model of BCP. Paw mechanical withdrawal threshold (PMWT) was measured before and after BCP. The effects of hPPE gene transfer on hBMSC bioactivity were analyzed in vitro and in vivo.Results. No changes were observed in the surface phenotypes and differentiation of hBMSCs after gene transfer. The hPPE-hBMSC group showed improved PMWT values on the ipsilateral side of rats with BCP from day 12 postoperatively, and the analgesic effect was reversed by naloxone. The levels of proinflammatory cytokines such as IL-1βand IL-6 were ameliorated, and leucine-enkephalin (L-EK) secretion was augmented, in the hPPE-engineered hBMSC group.Conclusion. The intrathecal administration of BMSCs modified with the hPPE gene can effectively relieve pain caused by bone cancer in rats and might be a potentially therapeutic tool for cancer-related pain in humans.
- 1 January 2017
- Published by Wiley in Pain Research and Management
- Vol. 2017, 1-11
Open AccessAntinociceptive Effect of Intrathecal Injection of Genetically Engineered Human Bone Marrow Stem Cells Expressing the Human Proenkephalin Gene in a Rat Model of Bone Cancer Pain
Background. This study aimed to investigate the use of human bone marrow mesenchymal stem cells (hBMSCs) genetically engineered with the human proenkephalin (hPPE) gene to treat bone cancer pain (BCP) in a rat model.Methods. Primary cultured hBMSCs were passaged and modified with hPPE, and the cell suspensions (6 × 106) were then intrathecally injected into a rat model of BCP. Paw mechanical withdrawal threshold (PMWT) was measured before and after BCP. The effects of hPPE gene transfer on hBMSC bioactivity were analyzed in vitro and in vivo.Results. No changes were observed in the surface phenotypes and differentiation of hBMSCs after gene transfer. The hPPE-hBMSC group showed improved PMWT values on the ipsilateral side of rats with BCP from day 12 postoperatively, and the analgesic effect was reversed by naloxone. The levels of proinflammatory cytokines such as IL-1βand IL-6 were ameliorated, and leucine-enkephalin (L-EK) secretion was augmented, in the hPPE-engineered hBMSC group.Conclusion. The intrathecal administration of BMSCs modified with the hPPE gene can effectively relieve pain caused by bone cancer in rats and might be a potentially therapeutic tool for cancer-related pain in humans.
- 27 January 2014
- Published by Elsevier in Brain Research
- Vol. 1554, 29-35
Role of ATP-sensitive potassium channels in modulating nociception in rat model of bone cancer pain
- 27 January 2014
- Published by Elsevier in Brain Research
- Vol. 1554, 29-35
Role of ATP-sensitive potassium channels in modulating nociception in rat model of bone cancer pain
- 14 November 2012
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 23 (16) , 952-957
Neuroprotective effects of 17β-estradiol associate with KATP in rat brain
Previous studies have indicated that estrogen protects the brain from ischemic damage and regulates K(ATP) channel activity; the present study was designed to address the involvement of K(ATP) channels in the neuroprotective effects of estrogen in focal cerebral ischemia: in experiment 1, K(ATP) mRNA and protein in the cortices of rats were compared among groups of ovariectomized rats (Ovx-1), Sham-operated rats (Sham-1), and ovariectomized rats administered 17β-estradiol (Estr-1). In experiment 2, neurobehavioral scores and infarct volume of rats were evaluated after middle cerebral artery occlusion in ovariectomized rats (Ovx-2), Sham-operated rats (Sham-2), ovariectomized female rats administered 17β-estradiol (Estr-2), and ovariectomized rats administered both 17β-estradiol and stereotactic injections of glibenclamide (Estr+G). Our results showed that the Kir6.2 and SUR1 mRNA and protein levels in the brain cortices of female ovariectomized rats were lower than those in Sham rats. However, the expression levels of Kir6.2 and SUR1 in brain cortices of ovariectomized rats recovered after supplementation with 17β-estradiol. The protective effects of 17β-estradiol were abolished by glibenclamide, a K(ATP) channel blocker. This indicates that estradiol significantly upregulates the expression of K(ATP) channel subunits and channel activity in the brain cortices of ovariectomized rats. This regulation is associated with the neuroprotective effects of estradiol.
- 14 November 2012
- Published by Wolters Kluwer Health in NeuroReport
- Vol. 23 (16) , 952-957
Neuroprotective effects of 17β-estradiol associate with KATP in rat brain
Previous studies have indicated that estrogen protects the brain from ischemic damage and regulates K(ATP) channel activity; the present study was designed to address the involvement of K(ATP) channels in the neuroprotective effects of estrogen in focal cerebral ischemia: in experiment 1, K(ATP) mRNA and protein in the cortices of rats were compared among groups of ovariectomized rats (Ovx-1), Sham-operated rats (Sham-1), and ovariectomized rats administered 17β-estradiol (Estr-1). In experiment 2, neurobehavioral scores and infarct volume of rats were evaluated after middle cerebral artery occlusion in ovariectomized rats (Ovx-2), Sham-operated rats (Sham-2), ovariectomized female rats administered 17β-estradiol (Estr-2), and ovariectomized rats administered both 17β-estradiol and stereotactic injections of glibenclamide (Estr+G). Our results showed that the Kir6.2 and SUR1 mRNA and protein levels in the brain cortices of female ovariectomized rats were lower than those in Sham rats. However, the expression levels of Kir6.2 and SUR1 in brain cortices of ovariectomized rats recovered after supplementation with 17β-estradiol. The protective effects of 17β-estradiol were abolished by glibenclamide, a K(ATP) channel blocker. This indicates that estradiol significantly upregulates the expression of K(ATP) channel subunits and channel activity in the brain cortices of ovariectomized rats. This regulation is associated with the neuroprotective effects of estradiol.